{"id":253096,"date":"2025-01-12T19:09:04","date_gmt":"2025-01-12T18:09:04","guid":{"rendered":"https:\/\/r3i.org\/serie-de-videos-riesgo-vascular-residual\/"},"modified":"2025-02-05T23:12:09","modified_gmt":"2025-02-05T22:12:09","slug":"serie-de-videos-riesgo-vascular-residual","status":"publish","type":"page","link":"https:\/\/r3i.org\/es\/serie-de-videos-riesgo-vascular-residual\/","title":{"rendered":"Serie de v\u00eddeos : Riesgo vascular residual"},"content":{"rendered":"

[et_pb_section fb_built=\u00bb1″ admin_label=\u00bbHeader\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bb35f37621-1062-4ae6-955d-76a3167a2aa8″ background_image=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/video-2562034_1280.jpg\u00bb parallax=\u00bbon\u00bb min_height=\u00bb158px\u00bb height=\u00bb225px\u00bb custom_padding=\u00bb6vw||6vw||true|false\u00bb collapsed=\u00bbon\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22background_color_gradient_stops%22%93}\u00bb][et_pb_row column_structure=\u00bb2_3,1_3″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb-69px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb2_3″ _builder_version=\u00bb4.27.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbSerie de v\u00eddeos\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbbe7faa8d-05f5-42a0-9582-c8e8739f13b6″ title_font=\u00bbPoppins||||||||\u00bb title_text_align=\u00bbleft\u00bb title_text_color=\u00bb#FFFFFF\u00bb title_font_size=\u00bb47px\u00bb custom_padding=\u00bb12px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_heading][\/et_pb_column][et_pb_column type=\u00bb1_3″ _builder_version=\u00bb4.27.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.27.3″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb-49px|||||\u00bb custom_padding=\u00bb2px||54px|||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_3_text_color=\u00bbgcid-primary-color\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22header_3_text_color%22%93}\u00bb]<\/p>\n

Riesgo vascular residual<\/h3>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb hover_enabled=\u00bb0″ global_colors_info=\u00bb{}\u00bb column_structure=\u00bb1_2,1_2″ sticky_enabled=\u00bb0″][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/Jean-Charles-Fruchart-film-3-1467.mp4″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfCu\u00e1les son las limitaciones de los ensayos con fibratos en el riesgo vascular residual?<\/h5>\n
2018 – Jean-Charles Fruchart<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/ANITSCHKOW_4.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb-44px||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Riesgo residual: la necesidad de un paso m\u00e1s all\u00e1 de \u00abcuanto m\u00e1s bajo, mejor<\/h5>\n
2008 – Jean-Charles Fruchart<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/Raul-Santos-film-1-1467.mp4″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfPor qu\u00e9 necesitamos un nuevo consenso sobre el riesgo vascular residual? \u00bfHa cambiado el perfil de riesgo? <\/h5>\n
2018 – Raoul Santos<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/Henry-Ginsberg-film-1-1467.mp4″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfQu\u00e9 es el riesgo vascular residual?<\/h5>\n
2018 – Henry Ginsberg<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/Raul-Santos-film-1-1467.mp4″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfPor qu\u00e9 necesitamos un nuevo consenso sobre el riesgo vascular residual? \u00bfHa cambiado el perfil de riesgo? <\/h5>\n
2018 – Raoul Santos<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/Henry-Ginsberg-film-1-1467.mp4″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfQu\u00e9 es el riesgo vascular residual?<\/h5>\n
2018 – Henry Ginsberg<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/Chris-Packard-film-1-1467.mp4″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfQu\u00e9 es el riesgo vascular residual y cu\u00e1les son los marcadores de este riesgo?<\/h5>\n
2018 – Chris Packard<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/Aruna-Pradhan-film1-1467.mp4″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfQu\u00e9 est\u00e1 cambiando en nuestra gesti\u00f3n del riesgo vascular residual?<\/h5>\n
2018 – Aruna Pradhan<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/Aruna-Pradhan-film-2-1467.mp4″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfC\u00f3mo identificamos qu\u00e9 pacientes se benefician m\u00e1s de una intervenci\u00f3n adicional al tratamiento actual?<\/h5>\n
2018 – Aruna Pradhan<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/Aruna-Pradhan-film-45-1467.mp4″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfQu\u00e9 podemos aprender de los ensayos cl\u00ednicos anteriores para probar nuevos agentes para el riesgo vascular residual?<\/h5>\n
2018 – Aruna Pradhan<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/Ridker_3.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

ESC 2017 El Dr. Ridker habla de la evoluci\u00f3n del riesgo cardiovascular residual<\/h5>\n
2017 – Paul Ridker<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/CRG-Q1-subtitle.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfPueden los cambios en el estilo de vida influir en el riesgo vascular residual?<\/h5>\n
2014 – C\u00e9sar Rodr\u00edguez Gilabert<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/CRG-Q2-subtitle.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfC\u00f3mo diferenciar\u00edas el riesgo vascular y el riesgo vascular residual: c\u00f3mo abordas cada riesgo?<\/h5>\n
2014 – C\u00e9sar Rodr\u00edguez Gilabert<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/DREAM_AZ_Q2.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfC\u00f3mo puedes explicar el riesgo residual observado en TNT y PROBARLO?<\/h5>\n
2013 – Alberto Zambon<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/DREAM_AK_Q1.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfEl riesgo residual es cl\u00ednicamente relevante?<\/h5>\n
2013 – Antony Keech<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/S2_3_MEET-THE-EXPERT_RR_6.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Reducci\u00f3n farmacol\u00f3gica del riesgo vascular residual: \u00bfQu\u00e9 podemos esperar de la reducci\u00f3n farmacol\u00f3gica de la hipertrigliceridemia?<\/h5>\n
2009 – Robert Rosenson<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/S2_3_MEET-THE-EXPERT_RR_5.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Reducci\u00f3n farmacol\u00f3gica del riesgo vascular residual: \u00bfCu\u00e1l es el impacto de la hipertrigliceridemia en las part\u00edculas LDL?<\/h5>\n
2009 – Robert Rosenson<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/S2_3_MEET-THE-EXPERT_RR_2.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Reducci\u00f3n Farmacol\u00f3gica del Riesgo Vascular Residual: \u00bfC\u00f3mo podemos conseguir que los individuos se traten con Niacina?<\/h5>\n
2009 – Robert Rosenson<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/S_15_global-challenge_mixe_3.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Desaf\u00edo global del riesgo vascular residual: TG\/HDL-C el factor olvidado<\/h5>\n
2009 – Jean Davignon<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/S_15_global-challenge_mixe_2.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Desaf\u00edo global del riesgo vascular residual: en lo m\u00e1s profundo de la placa<\/h5>\n
2009 – Jean Davignon<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/S_15_global-challenge_mixe_1.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Reducci\u00f3n farmacol\u00f3gica del riesgo vascular residual: \u00bfTenemos datos de resultados con la niacina?<\/h5>\n
2009 – Robert Rosenson<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/S2_3_MEET-THE-EXPERT_RR_1.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Reducci\u00f3n farmacol\u00f3gica del riesgo vascular residual: \u00bfCu\u00e1les son los efectos de los fibratos sobre las lipoprote\u00ednas?<\/h5>\n
2009 – Robert Rosenson<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/S2_1_MEET-THE-EXPERT_VB_4.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Evidencias actuales sobre los factores que producen riesgo vascular residual: \u00bfPor qu\u00e9 el cHDL no es un objetivo secundario candidato en pacientes con triglic\u00e9ridos elevados?<\/h5>\n
2009 – Virgil Brown<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/S2_1_MEET-THE-EXPERT_VB_3.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Pruebas actuales sobre los factores que producen riesgo vascular residual: \u00bfPredicen los niveles de colesterol HDL el riesgo en los ensayos con estatinas?<\/h5>\n
2009 – Virgil Brown<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/S2_1_MEET-THE-EXPERT_VB_2.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Pruebas actuales sobre los factores que producen riesgo vascular residual: \u00bfPredicen los niveles de triglic\u00e9ridos (TG) el riesgo en los ensayos con estatinas?<\/h5>\n
2009 – Virgil Brown<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/S2_1_MEET-THE-EXPERT_VB_1.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Evidencias actuales sobre los factores que producen riesgo vascular residual: \u00bfCu\u00e1les son los factores de riesgo modificables?<\/h5>\n
2009 – Virgil Brown<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/sacks_webinar_1_2.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Antecedentes: el tratamiento con estatinas deja un Riesgo vascular residual hudge<\/h5>\n
2009 – Frank Sacks<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/r3i_mission_and_will.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Misi\u00f3n de riesgo residual<\/h5>\n
2009 – Khalid Al-Rubeaan, Vladimir Christov, Gheorghe Andrei Dan, Michel Hermans, Masato Odawa<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/PC_1.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Nuevos conocimientos sobre el riesgo vascular residual relacionado con los l\u00edpidos<\/h5>\n
2009 – Mike Gibbs<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/old_r3i_future_approaches.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Futuros enfoques de la gesti\u00f3n del riesgo vascular<\/h5>\n
2009 – Robert Rosenson, Christoph Wanner, Gheorghe Andrei Dan, Khalid Al-Rubeaan, Virgil Brown<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/S_12_residual-risk-in-women-.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Riesgo residual en mujeres<\/h5>\n
2009 – Sonia Anand, Henry Ginsberg, Lale Tokgozoglu<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/S_14_residual_risk.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Riesgo residual, \u00bfestamos tratando demasiado tarde?<\/h5>\n
2009 – Virgil Brown, Michael Brown, Jean Davignon, Michel Hermans, Frank Sacks<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/R3I_brown_q1.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfCu\u00e1l es la raz\u00f3n para considerar el riesgo vascular residual?<\/h5>\n
2009 – Virgil Brown<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/webinbar_zambon_4.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Gestionar hoy el riesgo vascular residual<\/h5>\n
2009 – Alberto Zambon<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/R3I_rosenson_q1.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfQu\u00e9 papel desempe\u00f1a el exceso de part\u00edculas LDL en el Riesgo vascular residual?<\/h5>\n
2008 – Robert Rosenson<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/R3I_kwiterovitch_cannon_q2.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfCu\u00e1l es el riesgo residual observado en el estudio PROVE IT, que compar\u00f3 pravastatina 40 mg con atorvastatina 80 mg en pacientes con s\u00edndrome coronario agudo?<\/h5>\n
2008<\/spanaptos> – Peter Kwiterovitch, Christopher Cannon<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/5_1_Overview.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Actividades del proyecto R3i: Un ambicioso programa de educaci\u00f3n y comunicaci\u00f3n<\/h5>\n
2008 – Bart Staels, Alberto Zambon<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/3_3-What-is-the-best-level.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Tras los resultados de la terapia intensiva de reducci\u00f3n de la glucosa en el estudio ACCORD, \u00bfcu\u00e1l es el mejor nivel objetivo para reducir la HbA1c?<\/h5>\n
2008 – Paola Fioretto, Michel Hermans<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/5_1_Overview.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Actividades del proyecto R3i: Un ambicioso programa de educaci\u00f3n y comunicaci\u00f3n<\/h5>\n
2008 – Bart Staels, Alberto Zambon<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/3_3-What-is-the-best-level.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Tras los resultados de la terapia intensiva de reducci\u00f3n de la glucosa en el estudio ACCORD, \u00bfcu\u00e1l es el mejor nivel objetivo para reducir la HbA1c?<\/h5>\n
2008 – Paola Fioretto, Michel Hermans<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/3_2-STENO-2-corr-.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

El estudio STENO-2: abordar la cuesti\u00f3n del Riesgo Residual<\/h5>\n
2008 – Paola Fioretto<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/1_3-Residual-Risk-population.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfQui\u00e9n tiene riesgo vascular residual?<\/h5>\n
2008 – Michel Hermans, Alberto Zambon<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/1_2_residual_risk_definition.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Definici\u00f3n del riesgo residual<\/h5>\n
2008 – Paola Fioretto, Robert Rosenson, Frank Sacks, Bart Staels<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/R3I_brewer_q2.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfC\u00f3mo podemos reducir el riesgo residual?<\/h5>\n
2008 – Bryan Brewer<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/R3I_brewer_q1.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfPor qu\u00e9 debemos centrarnos en el Riesgo Residual?<\/h5>\n
2008 – Bryan Brewer<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/jupiter_3.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfC\u00f3mo identificar mejor a los pacientes con riesgo residual cardiovascular?<\/h5>\n
2008 – Vijay Nambi, Anand Rohatgi<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/jupiter_5.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

\u00bfQu\u00e9 objetivos biol\u00f3gicos para la gesti\u00f3n del riesgo residual macrovascular?<\/h5>\n
2008 – Christie Ballantyne, Peter Kwiterovitch<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/jupiter_6.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Estrategia de Reducci\u00f3n del Riesgo Residual<\/h5>\n
2008 – Bryan Brewer, Christopher Cannon, Peter Kwiterovitch<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/jupiter_4.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Comunicar sobre el riesgo cardiovascular<\/h5>\n
2008 – Lorie Mosca, Jarett Berry<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/1_1_R3I_call-to-action.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Una llamada a la acci\u00f3n de los Responsables del CSI<\/h5>\n
2008 – Jean-Charles Fruchart, Michel Hermans<\/spanaptos><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Riesgo vascular residual\u00bfCu\u00e1les son las limitaciones de los ensayos con fibratos en el riesgo vascular residual? 2018 – Jean-Charles FruchartRiesgo residual: la necesidad de un paso m\u00e1s all\u00e1 de \u00abcuanto m\u00e1s bajo, mejor 2008 – Jean-Charles Fruchart\u00bfPor qu\u00e9 necesitamos un nuevo consenso sobre el riesgo vascular residual? \u00bfHa cambiado el perfil de riesgo? 2018 – […]<\/p>\n","protected":false},"author":258497325,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-253096","page","type-page","status-publish","hentry"],"yoast_head":"\nSerie de v\u00eddeos : Riesgo vascular residual - R3I<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/r3i.org\/es\/serie-de-videos-riesgo-vascular-residual\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Serie de v\u00eddeos : Riesgo vascular residual - R3I\" \/>\n<meta property=\"og:description\" content=\"Riesgo vascular residual\u00bfCu\u00e1les son las limitaciones de los ensayos con fibratos en el riesgo vascular residual? 2018 - Jean-Charles FruchartRiesgo residual: la necesidad de un paso m\u00e1s all\u00e1 de "cuanto m\u00e1s bajo, mejor 2008 - Jean-Charles Fruchart\u00bfPor qu\u00e9 necesitamos un nuevo consenso sobre el riesgo vascular residual? \u00bfHa cambiado el perfil de riesgo? 2018 - […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/r3i.org\/es\/serie-de-videos-riesgo-vascular-residual\/\" \/>\n<meta property=\"og:site_name\" content=\"R3I\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-05T22:12:09+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"32 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/serie-de-videos-riesgo-vascular-residual\\\/\",\"url\":\"https:\\\/\\\/r3i.org\\\/es\\\/serie-de-videos-riesgo-vascular-residual\\\/\",\"name\":\"Serie de v\u00eddeos : Riesgo vascular residual - R3I\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#website\"},\"datePublished\":\"2025-01-12T18:09:04+00:00\",\"dateModified\":\"2025-02-05T22:12:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/serie-de-videos-riesgo-vascular-residual\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/r3i.org\\\/es\\\/serie-de-videos-riesgo-vascular-residual\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/serie-de-videos-riesgo-vascular-residual\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/r3i.org\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Serie de v\u00eddeos : Riesgo vascular residual\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/r3i.org\\\/es\\\/\",\"name\":\"R3I\",\"description\":\"Residual Risk Reduction Initiative\",\"publisher\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/r3i.org\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#organization\",\"name\":\"R3I\",\"url\":\"https:\\\/\\\/r3i.org\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/r3i.org\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/r3i-logo-transp-1.png?fit=1601%2C834&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/r3i.org\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/r3i-logo-transp-1.png?fit=1601%2C834&ssl=1\",\"width\":1601,\"height\":834,\"caption\":\"R3I\"},\"image\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Serie de v\u00eddeos : Riesgo vascular residual - R3I","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/r3i.org\/es\/serie-de-videos-riesgo-vascular-residual\/","og_locale":"es_ES","og_type":"article","og_title":"Serie de v\u00eddeos : Riesgo vascular residual - R3I","og_description":"Riesgo vascular residual\u00bfCu\u00e1les son las limitaciones de los ensayos con fibratos en el riesgo vascular residual? 2018 - Jean-Charles FruchartRiesgo residual: la necesidad de un paso m\u00e1s all\u00e1 de \"cuanto m\u00e1s bajo, mejor 2008 - Jean-Charles Fruchart\u00bfPor qu\u00e9 necesitamos un nuevo consenso sobre el riesgo vascular residual? \u00bfHa cambiado el perfil de riesgo? 2018 - […]","og_url":"https:\/\/r3i.org\/es\/serie-de-videos-riesgo-vascular-residual\/","og_site_name":"R3I","article_modified_time":"2025-02-05T22:12:09+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"32 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/r3i.org\/es\/serie-de-videos-riesgo-vascular-residual\/","url":"https:\/\/r3i.org\/es\/serie-de-videos-riesgo-vascular-residual\/","name":"Serie de v\u00eddeos : Riesgo vascular residual - R3I","isPartOf":{"@id":"https:\/\/r3i.org\/es\/#website"},"datePublished":"2025-01-12T18:09:04+00:00","dateModified":"2025-02-05T22:12:09+00:00","breadcrumb":{"@id":"https:\/\/r3i.org\/es\/serie-de-videos-riesgo-vascular-residual\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/r3i.org\/es\/serie-de-videos-riesgo-vascular-residual\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/r3i.org\/es\/serie-de-videos-riesgo-vascular-residual\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/r3i.org\/es\/"},{"@type":"ListItem","position":2,"name":"Serie de v\u00eddeos : Riesgo vascular residual"}]},{"@type":"WebSite","@id":"https:\/\/r3i.org\/es\/#website","url":"https:\/\/r3i.org\/es\/","name":"R3I","description":"Residual Risk Reduction Initiative","publisher":{"@id":"https:\/\/r3i.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/r3i.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/r3i.org\/es\/#organization","name":"R3I","url":"https:\/\/r3i.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/r3i.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/r3i.org\/wp-content\/uploads\/2024\/11\/r3i-logo-transp-1.png?fit=1601%2C834&ssl=1","contentUrl":"https:\/\/i0.wp.com\/r3i.org\/wp-content\/uploads\/2024\/11\/r3i-logo-transp-1.png?fit=1601%2C834&ssl=1","width":1601,"height":834,"caption":"R3I"},"image":{"@id":"https:\/\/r3i.org\/es\/#\/schema\/logo\/image\/"}}]}},"jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/Pgbfv2-13Qc","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/pages\/253096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/users\/258497325"}],"replies":[{"embeddable":true,"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/comments?post=253096"}],"version-history":[{"count":2,"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/pages\/253096\/revisions"}],"predecessor-version":[{"id":253098,"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/pages\/253096\/revisions\/253098"}],"wp:attachment":[{"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/media?parent=253096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}